CXCR4 and breast neoplasm: Preclinical studies of CXCR4 inhibitors have demonstrated its ability to attenuate the proliferation and metastasis of breast tumors; AMD3100 is a CXCR4 antagonist that decreases lung metastases in breast cancer (120).